A review of the therapeutic role of the new third-generation tki olverembatinib in chronic myeloid leukemia

HIGHLIGHTS

• who: Honglan Qian from the University of Texas MD Anderson Cancer Center, United States have published the paper: A review of the therapeutic role of the new third-generation TKI olverembatinib in chronic myeloid leukemia, in the Journal: (JOURNAL)
• what: Resistance to TKIs is a complex and multifactorial process that presents the selection of leukemia clones with the ability to evade treatment (47).
• how: In vitro data indicated that some compound mutations involving T315I also potentially impact ponatinib sensitivity . The authors declare that the research was conducted in the absence of any commercial . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.